Back to search

Article

The Impact of CYP3A5 Genotype on Tacrolimus Pharmacokinetics in Children following Heart Transplant

2026-02-12

Abstract excerpt

<title>Abstract</title> <p>Tacrolimus is a first-line immunosuppressant used after solid organ transplantation that suffers from extensive intra- and inter-patient variability and a narrow therapeutic window. Tacrolimus clearance is predominantly mediated by CYP3A4 and CYP3A5, with evidence indicating that pharmacogenetic (PG) differences in these enzymes drive significant changes in tacrolimus pharmacokinetics (...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e0e2bf82-16cf-5440-ba32-25820dbe64f8
DOI
10.21203/rs.3.rs-8780228/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Impact of CYP3A5 Genotype on Tacrolimus Pharmacokinetics in Children following Heart TransplantDOI 10.21203/rs.3.rs-8780228/v1
Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver TransplantationSemantic proximity
Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.Semantic proximity
CYP3A4/5 genotypes and age codetermine tacrolimus concentration and dosage in pediatric heart transplant recipients.Semantic proximity
Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.Semantic proximity
Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene PolymorphismsSemantic proximity
Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.Semantic proximity
Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.Semantic proximity
Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation.Semantic proximity
Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.Semantic proximity
Genotype Informed Bayesian Dosing of Tacrolimus in Paediatric Solid Organ Transplant IndividualsSemantic proximity
Impact of donor CYP3A5 genotype on pharmacokinetics of tacrolimus in South African paediatric liver transplant patients.Semantic proximity
GRWR Correlates with the Metabolism of Tacrolimus After Pediatric Living Donor Liver Transplantation Accorrding to Donor CYP3A5 PolymorphismSemantic proximity
Select a neighboring publication to make it the new centre.